home / stock / mycof / mycof news

MYCOF News and Press, New Age Brands From 09/15/22

Stock Information
Company Name: New Age Brands
Stock Symbol: MYCOF
Market: OTC
Website: mydecine.com
Menu
MYCOF MYCOF Quote MYCOF Short MYCOF News MYCOF Articles MYCOF Message Board
Get MYCOF Alerts

News, Short Squeeze, Breakout and More Instantly...
MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes First Tranche Under Subscription Agreement

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
MYCOF - MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Canada NewsWire DENVER , Sept. 14, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE...

MYCOF - Mydecine Sells Mindleap For C$4 Million

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced on Thursday that it has signed an LOI to sell its digital technology subsidiary, Mindleap Health Inc. to PanGenomic Health Inc. The deal is valued at C$4 million. “We are extremely pleased with what ...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Enters LOI for Sale of Mindleap Health

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
MYCOF - Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.

DENVER, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Enters Common Share Subscription Agreement

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has entered into...

MYCOF - Mydecine Innovations enters into $245M share subscription agreement, CFO resigns

Biotechnology company Mydecine Innovations Group ( OTCPK:MYCOF ) said it has entered into a share subscription agreement with a third party investor and that the current CFO has resigned. The investor has subscribed for ~327M shares at $0.75 per share for aggregate gross proce...
MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Private Placement; Interim Changes to Management and Board

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...

MYCOF - Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly addr...

MYCOF - Psilocybin Company Mydecine Shuts Down

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is basically shutting down as the company has burned through its cash and is closing its research operations in Denver Colorado. The psilocybin company reported financial results for the six months ending June 30, 2022, with ...
Previous 10 Next 10